CN114375307B - 产生抗α4β7抗体的方法 - Google Patents

产生抗α4β7抗体的方法

Info

Publication number
CN114375307B
CN114375307B CN202080049572.2A CN202080049572A CN114375307B CN 114375307 B CN114375307 B CN 114375307B CN 202080049572 A CN202080049572 A CN 202080049572A CN 114375307 B CN114375307 B CN 114375307B
Authority
CN
China
Prior art keywords
vedolizumab
composition
less
hours
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080049572.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN114375307A (zh
Inventor
D·阿梅利
S·R·卡特
M·E·多兰
N·希洛
A·坤杜
A·米勒
G·帕克斯
O·佩利
P·巴蒂亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to CN202510051206.5A priority Critical patent/CN119859188A/zh
Priority to CN202511678992.8A priority patent/CN121736106A/zh
Publication of CN114375307A publication Critical patent/CN114375307A/zh
Application granted granted Critical
Publication of CN114375307B publication Critical patent/CN114375307B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080049572.2A 2019-06-10 2020-06-10 产生抗α4β7抗体的方法 Active CN114375307B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202510051206.5A CN119859188A (zh) 2019-06-10 2020-06-10 产生抗α4β7抗体的方法
CN202511678992.8A CN121736106A (zh) 2019-06-10 2020-06-10 产生抗α4β7抗体的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962859494P 2019-06-10 2019-06-10
US62/859,494 2019-06-10
PCT/US2020/037059 WO2020252069A1 (en) 2019-06-10 2020-06-10 METHODS OF PRODUCING AN ANTI-α4β7 ANTIBODY

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202511678992.8A Division CN121736106A (zh) 2019-06-10 2020-06-10 产生抗α4β7抗体的方法
CN202510051206.5A Division CN119859188A (zh) 2019-06-10 2020-06-10 产生抗α4β7抗体的方法

Publications (2)

Publication Number Publication Date
CN114375307A CN114375307A (zh) 2022-04-19
CN114375307B true CN114375307B (zh) 2025-12-05

Family

ID=73781728

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080049572.2A Active CN114375307B (zh) 2019-06-10 2020-06-10 产生抗α4β7抗体的方法
CN202510051206.5A Pending CN119859188A (zh) 2019-06-10 2020-06-10 产生抗α4β7抗体的方法
CN202511678992.8A Pending CN121736106A (zh) 2019-06-10 2020-06-10 产生抗α4β7抗体的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202510051206.5A Pending CN119859188A (zh) 2019-06-10 2020-06-10 产生抗α4β7抗体的方法
CN202511678992.8A Pending CN121736106A (zh) 2019-06-10 2020-06-10 产生抗α4β7抗体的方法

Country Status (14)

Country Link
US (1) US20220267449A1 (https=)
EP (1) EP3980466A4 (https=)
JP (2) JP7624414B2 (https=)
CN (3) CN114375307B (https=)
AR (1) AR119270A1 (https=)
AU (1) AU2020290943A1 (https=)
BR (1) BR112021024897A2 (https=)
CA (1) CA3143167A1 (https=)
IL (1) IL288825A (https=)
MA (1) MA56129A (https=)
MX (1) MX2021015300A (https=)
PL (1) PL439809A1 (https=)
TW (1) TW202112818A (https=)
WO (1) WO2020252069A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12433947B2 (en) 2018-04-10 2025-10-07 Dr. Reddy's Laboratories Limited Stable formulations of therapeutic antibody
WO2019198099A1 (en) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Stable antibody formulation
WO2023007516A1 (en) * 2021-07-29 2023-02-02 Dr. Reddy’S Laboratories Limited Method to control high molecular weight aggregates in an antibody composition
EP4380948A4 (en) * 2021-08-05 2025-07-16 Dr Reddys Laboratories Ltd METHOD FOR PURIFYING AN ANTIBODY COMPOSITION BY MEANS OF CATION EXCHANGE CHROMATOGRAPHY
WO2023031965A1 (en) * 2021-09-03 2023-03-09 Dr. Reddy’S Laboratories Limited Method to obtain a purified antibody composition
WO2024233992A2 (en) * 2023-05-11 2024-11-14 Trophogen, Inc. Methods of manufacturing highly glycosylated glycoprotein hormones and their analogs
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2014142882A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
PL3116891T3 (pl) * 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Aspartate Isomerization in the Complementarity-Determining Regions of Two Closely Related Monoclonal Antibodies;Aditya A. Wakankar et al.;《Biochemistry》;20070201;第46卷(第6期);第1534-1544页 *
Identification of multiple sources of charge heterogeneity in a recombinant antibody;Reed J. Harrisa et al.;《Journal of Chromatography B》;20010310;第752卷(第2期);第233-245页 *

Also Published As

Publication number Publication date
BR112021024897A2 (pt) 2022-01-18
PL439809A1 (pl) 2022-12-05
CN121736106A (zh) 2026-03-27
TW202112818A (zh) 2021-04-01
EP3980466A4 (en) 2023-06-07
WO2020252069A1 (en) 2020-12-17
JP7624414B2 (ja) 2025-01-30
CA3143167A1 (en) 2020-12-17
CN119859188A (zh) 2025-04-22
US20220267449A1 (en) 2022-08-25
EP3980466A1 (en) 2022-04-13
JP2025063035A (ja) 2025-04-15
MX2021015300A (es) 2022-02-03
AU2020290943A1 (en) 2022-02-03
JP2022536486A (ja) 2022-08-17
CN114375307A (zh) 2022-04-19
AR119270A1 (es) 2021-12-09
MA56129A (fr) 2022-04-13
IL288825A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
CN114375307B (zh) 产生抗α4β7抗体的方法
US20230060770A1 (en) Cation exchange chromatography wash buffer
US10688412B2 (en) Affinity chromatography wash buffer
TW201348247A (zh) 利用蛋白質ａ親和性層析之非人類抗體之新穎純化
KR20130131307A (ko) 단백질 정제
CN107446044B (zh) 一种纯化抗体的方法及所用缓冲液
CN114025843B (zh) 抗体纯化方法及其组合物
US12139510B2 (en) Process of purification of protein
JP2022536486A5 (https=)
US20250296014A1 (en) An improved process of purification of protein
CN111704670B (zh) 重组抗RANKL抗体IgG2型的二硫键异构体及其纯化方法
RU2852606C2 (ru) СПОСОБЫ ПОЛУЧЕНИЯ АНТИТЕЛА ПРОТИВ α4β7
US20250296015A1 (en) An improved process of purification of protein
US20260116917A1 (en) Process of purification of protein

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant